Quality of life survey in patients with advanced prostate cancer

Experimental Oncology

Volumn 27, Issue 1, 2005, Pages 13-17

  Giannakopoulos, Xenophon ^a   Charalabopoulos, Konstantinos ^a   Charalabopoulos, Alexandros ^a   Golias, Christos ^a   Peschos, Dimitrios ^a   Sofikitis, Nikolaos ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Advanced prostate cancer; Quality of life (QoL)

Indexed keywords

ANALGESIC AGENT; ANTIANDROGEN; BICALUTAMIDE; CALCITRIOL; DOCETAXEL; FLUTAMIDE; GONADORELIN AGONIST; RECOMBINANT ERYTHROPOIETIN;

ADVANCED CANCER; ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CASTRATION; CLINICAL PRACTICE; CLINICAL TRIAL; COST OF ILLNESS; DAILY LIFE ACTIVITY; DRUG EFFICACY; FATIGUE; HOT FLUSH; HUMAN; LIBIDO DISORDER; MEDICAL DECISION MAKING; MICTURITION; ORCHIECTOMY; OSTEOPOROSIS; PAIN ASSESSMENT; PATIENT SATISFACTION; PROSTATE CANCER; PSYCHOSOCIAL DISORDER; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SIDE EFFECT;

HUMANS; MALE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 17444428886     PISSN: 02043564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Osoba D. Lesson learned from measuring health - related quality of life in oncology. J Clin Oncol 1994; 12: 608-16.
2. Calais de Silva F, Reis E, Costa T, Denis L and the members of the quality of life committee of the EORTC Genitourinary Group: quality of life in patients with prostate cancer. A feasibility study. Cancer (suppl) 1993; 73: 1138-42.
3. Fossa SD, Aaronson NK, Newling D, van Cangh PJ, Denis L, Kurth KH, de Pauw M. Quality of life and treatment of hormone resistant metastatic prostate cancer. The EORTC Genito-Urinary Group. Eur J Cancer 1990; 26: 1133-6.
4. Slevin ML, Plant H, Lynch D. Who should measure quality of life the doctor or the patient? Br J Cancer 1988; 57: 107-12.
5. Doehn C, Jocham D. Quality of life in urologic oncology: new aspects. Onkologie 2003; 26: 30-4.
6. De Haes JCJM, van Knippenberg FCE, Neijt JP. Measuring psychological and physical distress in cancer patients: Structure and application of the Rotterdam symptom checklist. Br J Cancer 1990; 62: 1034-8.
7. Fournier G. Management of advanced prostate cancer. Rev Prat 1994; 44: 595-600.
8. Bertetto O, Bracarda S, Tamburini M, Cortesi E. Quality of life studies and genito-urinary tumors. Ann Oncol 2001; 12: 43-8.
9. Green HJ, Pakenham KI, Headley BC, Gardiner RA. Coping and health-related quality of life in men with prostate cancer randomly assigned to hormonal medication or close monitoring. Psychooncology 2002; 11: 401-14.
10. Droz JP, Flechon A, Terret C. Metastatic prostate cancer. Rev Prat 2003; 53: 2258-62.
11. Albertsen PC, Aaronson NK, Muller MJ, Keller SD, Ware JE Jr. Health-related quality of life among patients with metastatic prostate cancer. Urology 1997; 49: 207-16.
12. Ginchuk VG, Balitskii KP. Mechanisms of metastasis and factors in antimetastatic resistance. Exp Oncol 1988; 10: 22-4.
13. Baltogiannis D, Giannakopoulos X, Charalabopoulos K, Sofikitis N. Monotherapy in advanced prostate cancer: an overview. Exp Oncol 2004; 26: 185-91.
14. Holzbeierlein JM, Castle EP, Thrasher JB. Complications of androgen-deprivation therapy for prostrate cancer. Clin Prostate Cancer 2003; 2: 147-52.
15. Efficace F, Bottomley A, van Andel G. Health related quality of life in prostate carcinoma patients: a systematic review of randomized controlled trials. Cancer 2003; 97: 377-88.
16. Scalliet PG, Remouchamps V, Curran D, Ledent G, Wambersie A, Richard F, van Cangh P. Retrospective analysis of results of p (65) +Be neutron therapy for treatment of prostate adenocarcinoma at the cyclotron of Louvain-1a-Leuve. Part II: Side effects and their influence on quality of life measured with QLQ-C30 of EORTC. Int J Radiat Oncol Biol Phys 2004; 58: 1549-61.
17. Crowe H, Costello AJ. Prostrate cancer: perspectives on quality of life and impact of treatment on patients and their partners. Urol Nurs 2003; 23: 279-85.
18. Denis L, Robinson M, Mahler C. Protocol for a randomized prospective study of the treatment of patients with metastatic prostatic cancer to compare the therapeutic effect of orchiectomy versus LHRH- analog depot (Zoladex) preparation supplemented by an anti-androgen: protocol no. 30853. Brussels: EORTC Genitourinary Group, 1986.
19. Aaronson NK. EORTC protocol 15861: Development of core quality of life questionnaire for use in cancer trial. Brussels: EORTC Data Center, 1987.
20. Beer TM, Eilers KM, Garzotto M, Hsieh YC, Mori M. Quality of life and pain relief during treatment with calcitriol and docetaxel in symptomatic metastatic androgen-independent prostate carcinoma. Cancer 2004; 100: 758-63.
21. Queipo Zaragoza JA, Chicote Perez F, Beltran Meseguer JF, Borrell Palanca A, Giner Marco V, Esteve Claramunt J, Pastor Sempere F. Improvement of anemia and quality of life of patients with prostate cancer by treatment with human recombinant erythropoietin. Arch Exp Urol 2004; 57: 35-40.
22. Hjermstad MJ, Fossa SD, Bjordal K, Kaasa S. Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire. J Clin Oncol 1995; 13: 1249-54.
23. Fossa SD, Aaronson NK, Newling D. Quality of life treatment of hormone resistant metastatic prostate cancer. Eur J Cancer 1989; 26: 1133-6.
24. Aaronson NK, Ahmedzai S, Bergman B. The European Organization for Research and Treatment of CANCER QLC-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
25. Rohde V, Wellmann A, Fogt F. Economical data and advanced prostate carcinoma: do we need new guidelines for decision-making? Oncol Rep 2002; 9: 1185-8.